Cocrystal Pharma Shares Fall After Flu-Treatment Study Is Extended

Dow Jones2024-12-31

By Sabela Ojea

Cocrystal Pharma shares dropped after the company said it planned to extend a study of an oral treatment for influenza because of an unexpectedly low rate of infection in participants challenged with a strain of the virus.

The Bothell, Wash., biotechnology company's shares were down 25% at $2.43 in premarket trading Tuesday. The stock was up about 89% from the start of the year, as of Monday's market close.

Cocrystal said it would extend enrollment in the Phase 2a human challenge study of the CDI-42344 drug candidate for pandemic avian and seasonal influenza A infections because the low rate of infection hindered data analysis.

"The establishment of robust influenza infection in healthy, uninfected study subjects is critical to determine clinical endpoints for evaluating antiviral molecules," Co-Chief Executive Sam Lee said.

Lee added that the company remained optimistic about the treatment's prospects, and was encouraged by its favorable safety and tolerability profile so far.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

December 31, 2024 09:01 ET (14:01 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2495461866?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-31 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2495461866","market":"nz","top_or_hot":-1,"title":"Cocrystal Pharma Shares Fall After Flu-Treatment Study Is Extended","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Cocrystal Pharma shares dropped after the company said it planned to extend a study of an oral treatment for influenza because of an unexpectedly low rate of infection in participants challenged with a strain of the virus. \n</p>\n<p>\n  The Bothell, Wash., biotechnology company's shares were down 25% at $2.43 in premarket trading Tuesday. The stock was up about 89% from the start of the year, as of Monday's market close. \n</p>\n<p>\n  Cocrystal said it would extend enrollment in the Phase 2a human challenge study of the CDI-42344 drug candidate for pandemic avian and seasonal influenza A infections because the low rate of infection hindered data analysis. \n</p>\n<p>\n  \"The establishment of robust influenza infection in healthy, uninfected study subjects is critical to determine clinical endpoints for evaluating antiviral molecules,\" Co-Chief Executive Sam Lee said. \n</p>\n<p>\n  Lee added that the company remained optimistic about the treatment's prospects, and was encouraged by its favorable safety and tolerability profile so far. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 31, 2024 09:01 ET (14:01 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cocrystal Pharma Shares Fall After Flu-Treatment Study Is Extended</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCocrystal Pharma Shares Fall After Flu-Treatment Study Is Extended\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-31 22:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Sabela Ojea \n\n\n \n\n\n  Cocrystal Pharma shares dropped after the company said it planned to extend a study of an oral treatment for influenza because of an unexpectedly low rate of infection in ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2495461866","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2495461866","pubTimestamp":1735653660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Cocrystal Pharma shares dropped after the company said it planned to extend a study of an oral treatment for influenza because of an unexpectedly low rate of infection in participants challenged with a strain of the virus.The Bothell, Wash., biotechnology company's shares were down 25% at $2.43 in premarket trading Tuesday. The stock was up about 89% from the start of the year, as of Monday's market close.Cocrystal said it would extend enrollment in the Phase 2a human challenge study of the CDI-42344 drug candidate for pandemic avian and seasonal influenza A infections because the low rate of infection hindered data analysis.\"The establishment of robust influenza infection in healthy, uninfected study subjects is critical to determine clinical endpoints for evaluating antiviral molecules,\" Co-Chief Executive Sam Lee said.Lee added that the company remained optimistic about the treatment's prospects, and was encouraged by its favorable safety and tolerability profile so far.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"流感治疗研究延长后Cocrystal Pharma股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COCP":0.9},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Cocrystal Pharma shares dropped after the company said it planned to extend a study of an oral treatment for influenza because of an unexpectedly low rate of infection in participants challenged with a strain of the virus. \n\n\n  The Bothell, Wash., biotechnology company's shares were down 25% at $2.43 in premarket trading Tuesday. The stock was up about 89% from the start of the year, as of Monday's market close. \n\n\n  Cocrystal said it would extend enrollment in the Phase 2a human challenge study of the CDI-42344 drug candidate for pandemic avian and seasonal influenza A infections because the low rate of infection hindered data analysis. \n\n\n  \"The establishment of robust influenza infection in healthy, uninfected study subjects is critical to determine clinical endpoints for evaluating antiviral molecules,\" Co-Chief Executive Sam Lee said. \n\n\n  Lee added that the company remained optimistic about the treatment's prospects, and was encouraged by its favorable safety and tolerability profile so far. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 31, 2024 09:01 ET (14:01 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2495461866"}